This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Nuvo Pharmaceuticals Future Growth

Future criteria checks 0/6

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth20.3%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nuvo Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

DB:23N - Analysts future estimates and past financials data (CAD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/202272151516N/A
6/30/202271-31516N/A
3/31/202270-121617N/A
12/31/202169-322121N/A
9/30/202168-242223N/A
6/30/202168-92425N/A
3/31/202164-202222N/A
12/31/202074-42324N/A
9/30/202076-72525N/A
6/30/20207802121N/A
3/31/20207991818N/A
12/31/201970322N/A
9/30/201955-1-12-12N/A
6/30/201941-8-14-14N/A
3/31/201930-13-12-12N/A
12/31/201820-6-6-4N/A
9/30/201820-215N/A
6/30/2018180-22N/A
3/31/201815-1-31N/A
12/31/201718224N/A
9/30/201719401N/A
6/30/201721545N/A
3/31/201726845N/A
12/31/201627744N/A
9/30/2016291011N/A
6/30/20162911N/A-2N/A
3/31/2016248N/A-9N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 23N's forecast earnings growth is above the savings rate (0.2%).

Earnings vs Market: Insufficient data to determine if 23N's earnings are forecast to grow faster than the German market

High Growth Earnings: Insufficient data to determine if 23N's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 23N's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 23N's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 23N's Return on Equity is forecast to be high in 3 years time


Discover growth companies